Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07360782
NA

Personalized Pulsed Radiofrequency of the Greater Occipital Nerve for Medication Overuse Headache

Sponsor: Ankara City Hospital Bilkent

View on ClinicalTrials.gov

Summary

This study evaluates a novel treatment approach for medication overuse headache (MOH) using greater occipital nerve pulsed radiofrequency (GONPRF). Three treatment strategies are compared: Standard Treatment: Limitation of overused acute headache medications, lifestyle counseling, and continuation of existing preventive medications. Primary GONPRF: GONPRF administered in addition to standard treatment. Modified GONPRF: GONPRF administered as a second-line intervention in individuals who do not respond adequately to standard treatment alone. The study assesses whether GONPRF, when applied early or after an initial period of standard care, reduces monthly headache days more rapidly and effectively than standard treatment alone. Outcomes are evaluated over a 6-month follow-up period using headache diaries and scheduled clinical assessments. This is a randomized controlled trial designed to systematically evaluate the clinical benefit of GONPRF in patients with medication overuse headache.

Official title: Individualized Application of Occipital Nerve Pulsed Radiofrequency in Medication Overuse Headache: A Randomized Controlled Evaluation

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-01-26

Completion Date

2027-08

Last Updated

2026-01-27

Healthy Volunteers

No

Interventions

PROCEDURE

Greater Occipital Nerve Pulsed Radiofrequency

GONPRF applied at C2 under ultrasound guidance in addition to standard care, starting at enrollment. Follow-up at 1, 3, and 6 months.

OTHER

Standard care

Limitation of overused acute headache medications, lifestyle advice (nutrition, hydration, activity, sleep), and continuation of preventive medications. Participants who respond at 1 month continue standard care.

Locations (1)

Ankara Bilkent City Hospital

Ankara, Turkey (Türkiye)